Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720209 | 0.92 | GCK (1.00) | GCKKCNH2 | |
| SCHEMBL1721794 | 0.85 | GCK (0.85) | GCKKCNH2 | |
| SCHEMBL15015847 | 0.83 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL1720618 | 0.82 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL13180893 | 0.81 | GCK (0.68) | GCKKCNH2 | |
| Nerigliatin SCHEMBL1720691 | 0.78 | GCK (1.00) | GCKKCNH2 | |
| Nerigliatin SCHEMBL29411291 | 0.78 | GCK (1.00) | GCKKCNH2 | |
| SCHEMBL644929 | 0.76 | GCK (0.83) | GCKKCNH2 | |
| SCHEMBL1720702 | 0.76 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL13175416 | 0.76 | GCK (0.74) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406253-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | claimed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | claimed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | claimed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2604604-A1 | Benzofuranyl derivatives used as glucokinase inhibitors | Pfizer Inc (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8455496-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455496-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455496-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2406253-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234285-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | GCK 1/4885KCNH2 1501/4885 |
| US-20130252973-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | GCK 1/4885KCNH2 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.